title: High expression of microRNA-200c predicts poor clinical outcome in diffuse             large B-cell lymphoma.
abstract: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of B-cell             lymphomas. A new and important tool for understanding the biology and clinical             course of DLBCL is microRNA expression. This study presents microRNA-200c expression             data from 61 DLBCL patients treated with CHOP or R-CHOP. Patients with high microRNA-200c             expression had a median survival of 20.3 months and a significantly shorter overall             survival (P=0.019) compared to patients with low microRNA-200c expression, who             had a median survival of 35.8 months. We also found that patients treated with             R-CHOP only and displaying high microRNA-200c expression had a significantly shorter             overall survival compared to patients with low microRNA-200c expression, where             all patients were still alive at the time of the last follow-up (P=0.0036). Lastly,             we found that patients with high microRNA-200c expression had a significantly             shorter time from initial diagnosis to the first relapse compared to patients             with low microRNA-200c expression (P=0.0001). To our knowledge, this is the first             study showing that the expression of microRNA-200c affects the clinical outcome             of DLBCL patients, and that microRNA-200c is involved in the biology of DLBCL             development, although larger studies are necessary to confirm this. Further investigations             may also help to elucidate the biological role of microRNA-200c in DLBCL.
authors.affiliation: Department of Radiology, Oncology and Radiation Sciences, Uppsala                     University, Uppsala, Sweden.
authors.forename: Mattias
authors.initials: M
authors.lastname: Berglund
authors.forename: Gustav
authors.initials: G
authors.lastname: Hedström
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Amini
authors.forename: Gunilla
authors.initials: G
authors.lastname: Enblad
authors.forename: Ulf
authors.initials: U
authors.lastname: Thunberg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D015870:Gene Expression; D006801:Humans; D053208:Kaplan-Meier Estimate; D008198:Lymph Nodes / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone